{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "Dealbook", "byline": {"original": "By ROBERT CYRAN", "person": [{"rank": 1, "role": "reported", "firstname": "Robert", "organization": "", "lastname": "CYRAN"}]}, "abstract": "The pharmaceutical giant\u2019s $15 billion purchase of Hospira should bolster Pfizer\u2019s own generics unit \u2013 and open the way for spinning it off, says Robert Cyran of Reuters Breakingviews.", "type_of_material": "Blog", "word_count": "391", "lead_paragraph": null, "pub_date": "2015-02-05T14:10:05Z", "document_type": "blogpost", "slideshow_credits": null, "headline": {"main": "A Deal That Could Reverse Pfizer's History of Value-Destroying Acquisitions", "kicker": "DealBook"}, "snippet": "The pharmaceutical giant\u2019s $15 billion purchase of Hospira should bolster Pfizer\u2019s own generics unit \u2013 and open the way for spinning it off, says Robert Cyran of Reuters Breakingviews.", "multimedia": [{"height": 126, "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 800, "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "800", "xlarge": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/02/06/business/dbpix-drug-hospira1/dbpix-drug-hospira1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://dealbook.nytimes.com/2015/02/05/a-deal-that-could-reverse-pfizers-history-of-value-destroying-acquisitions/", "keywords": [{"rank": "1", "value": "Read, Ian C", "name": "persons"}, {"rank": "1", "value": "Hospira Inc", "name": "organizations"}, {"rank": "2", "value": "Pfizer Inc", "name": "organizations"}, {"rank": "3", "value": "Warner-Lambert Co", "name": "organizations"}, {"rank": "1", "value": "Biotechnology and Bioengineering", "name": "subject"}, {"rank": "2", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}], "blog": [], "_id": "54d3c03838f0d873d358e478", "source": "The New York Times"}